ProCE Banner Activity

Tardive Dyskinesia Etiology: Risks and Considerations

Podcast Episodes
Listen to this interprofessional discussion of the various risk factors for tardive dyskinesia&mdash including those beyond antipsychotic use&mdash and how the etiology of the disease might impact treatment approach.

Released: December 29, 2022

Expiration: December 28, 2023

Share

Faculty

Christoph U. Correll

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
New York, New York
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany

John M. Kane

John M. Kane, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York
Co-Director, Institute for Behavioral Science, Feinstein Institutes for Medical Research
Northwell Health
Glen Oaks, New York

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Neurocrine Biosciences

Faculty Disclosure

Primary Author

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
New York, New York
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany

Christoph U. Correll, MD: consultant/advisor: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sun Pharma, Sunovion, Supernus, Takeda, Teva, Viatris; expert testimony: Janssen, Otsuka; data safety monitoring board: Lundbeck, Relmada, Reviva, Rovi, Supernus, Teva; grant support: Janssen, Takeda; stock options: Cardio Diagnostics, Mindpax, LB Pharma, Quantic.

John M. Kane, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York
Co-Director, Institute for Behavioral Science, Feinstein Institutes for Medical Research
Northwell Health
Glen Oaks, New York

John M. Kane, MD: researcher: H. Lundbeck, Janssen, Otsuka; consultant: Alkermes, Allergan, Dainippon Sumitomo, H. Lundbeck, Intra-Cellular Therapies, Janssen, LB Pharmaceuticals, Lyndra, Merck, Neurocrine Biosciences, Otsuka, Reviva, Roche, Saladex, Sunovion, Takeda, Teva; ownership interest: LB Pharmaceuticals, Merck, Minerva, North Shore Therapeutics; fees for non-CME/CE services: Dainippon Sumitomo, H. Lundbeck, Janssen, Otsuka.